Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application of Flurbiprofen Axetil Injection was approved by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The approved indication is for post-surgical and cancer-related analgesia.